Complete response of multiple unresectable liver metastases from ascending colon cancer treated with FOLFIRI plus bevacizumab as third-line treatment
详细信息 查看全文
- 作者：Yasushi Ohmura (1) (2)
Kenjiro Kumano (1)
Shinichiro Watanabe (1)
Yoko Tabuchi (1)
Naoshi Mitsuoka (1)
Tetsuo Watanabe (1) - 关键词：Colon cancer ; Complete response ; Bevacizumab ; FOLFIRI
- 刊名：International Cancer Conference Journal
- 出版年：2014
- 出版时间：April 2014
- 年：2014
- 卷：3
- 期：2
- 页码：81-86
- 全文大小：
- 参考文献：1. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041-047 CrossRef
2. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-0 CrossRef
3. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-5 CrossRef
4. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-45 CrossRef
5. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-664 CrossRef
6. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-544 CrossRef
7. Chen HX, Mooney M, Boron M et al (2006) Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24:3354-360 CrossRef
8. Kang BW, Kim TW, Lee JL et al (2009) Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol 26:32-7 CrossRef
9. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-342 CrossRef
10. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-019 CrossRef
11. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-43 CrossRef
12. Adam R, Wicherts DA, de Haas RJ et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26:1635-641 CrossRef
13. Benoist S, Brouquet A, Penna C et al (2006) Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24:3939-945 CrossRef
14. Kriegel I, Cottu PH, Fourchotte V et al (2011) Wound healing and catheter thrombosis after implantable venous access device placement in 266 breast cancers treated with bevacizumab therapy. Anticancer Drugs 22:1020-023 CrossRef
15. Geva R, Vecchione L, Tejpar S et al (2013) Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer. Onco Targets Ther 6:53-8 - 作者单位：Yasushi Ohmura (1) (2)
Kenjiro Kumano (1)
Shinichiro Watanabe (1)
Yoko Tabuchi (1)
Naoshi Mitsuoka (1)
Tetsuo Watanabe (1)
1. Department of Surgery, Watanabe Hospital, Uwanari 539-5, Tamashima, Kurashiki, Okayama, 713-8101, Japan
2. Department of Surgery, Okayama Rosai Hospital, 1-10-25 Chikkou-Midorimachi, Minami-ku, Okayama, Japan - ISSN：2192-3183
文摘
The introduction of monoclonal antibodies into the treatment protocols for metastatic colorectal cancer has significantly improved outcomes. Bevacizumab, a monoclonal antibody for VEGF, combined with chemotherapy improved survival in previously untreated metastatic colorectal cancer, but according to the results of previous clinical studies it is recommended to use bevacizumab in combination with other chemotherapy as either first- or second-line treatment. We herein report a case of a complete response for approximately 5?years after having received treatment consisting of FOLFIRI plus bevacizumab as third-line chemotherapy for unresectable liver metastases from ascending colon cancer. A 61-year-old female with uncontrollable high fever over 40?°C was treated as having advanced ascending colon cancer with multiple liver metastases. After resection of primary tumor, her high grade fever persisted, and contrast-enhanced computed tomography (CE-CT) examination revealed progression of the liver tumors in spite of mFOLFOX6 and FOLFIRI administration. After failure of these treatments, bevacizumab was supplemented with FOLFIRI regimen as third-line chemotherapy. Just after the first administration of bevacizumab, pyrexia dramatically disappeared and her appetite and activity improved. The tumor state was evaluated by repeated CE-CT and revealed multiple liver tumors reduced in size and reduced enhancement around the tumors. After 8 courses of this treatment, complete response was noted. A total of 58 courses were administered and then discontinued at the patient’s request. There has been no sign of recurrence to date, i.e., for approximately 5?years after administration of FOLFIRI plus bevacizumab regimen. According to our experience, bevacizumab might have the potential to control tumor progression of colon cancer even in third-line treatment. In the latest National Comprehensive Cancer Network guideline, anti-EGFR antibody treatment is described as one of the first-line treatments and the role of bevacizumab in the late phase as molecules target the therapeutic agent after anti-EGFR antibody failure might be important and should be reevaluated.